Immix Biopharma Receives Tepid Wall Street Reception in IPO Debut

Pat Maio
Pat Maio has held various reporting and editorial management positions over the past 25 years, having specialized in business and government reporting. He has held reporting jobs with the San Diego Union-Tribune, Orange County Register, Dow Jones News and other newspapers in Ohio, West Virginia, Maryland and Washington, D.C.
Immix Biopharma Receives Tepid Wall Street Reception in IPO Debut
Photo by National Cancer Institute on Unsplash

Immix Biopharma Inc., a Santa Monica-based biotechnology company, got slammed in its trading debut this week, losing 27% of its value in its first day of trading on Nasdaq.

On Friday, the tiny biotech’s stock closed at $4 a share, a recovery of about 9% from its previous opening day’s close.


The nine-year-old company, which is known for its tissue-specific therapeutics that aims to help doctors rely less on traditional chemotherapy, was cofounded by Ilya Rachman, a physician at the world renowned Cedars-Sinai Medical Center in Los Angeles.

Immix raised $21 million in its IPO.

Proceeds from the IPO will be used to fund clinical trials for several of its cancer therapeutics that target tumors, colorectal cancer and soft tissue sarcoma. It’s planning several trials of its therapies, or medical treatments, in 2022.

Overall, the company is focusing its research on soft-tissue sarcomas, which are a group of cancers found in blood vessels, fat cells and the lining of joints.

Gabriel Morris, chief financial officer of Immix, did not return phone calls seeking comment on his company’s initial public offering, or IPO, and its tepid reception that it received on Wall Street.

In an email, Morris wrote Friday that the company is in a regulatory and legal “quiet period” which prohibits the company from making any public statements for another 25 days.

In 2020, the early stage growth company with a market capitalization of $26.4 million, reported a loss of $1.1 million. It also reported a loss of $1.6 million in its first nine months of 2021.

In filings with the U.S. Securities and Exchange Commission, Immix says that its competitors include biotech firms like Kymera Therapeutics Inc.; Morphic Holding Inc.; RAPT Therapeutics Inc.; Arena Pharmaceuticals Inc.; Landos Biopharma Inc.; and, Seres Therapeutics Inc.

dot.LA reporter Keerthi Vedantam contributed to this post.

Subscribe to our newsletter to catch every headline.

How Women’s Purchasing Power Is Creating a New Wave of Economic Opportunities In Sports

Samson Amore

Samson Amore is a reporter for dot.LA. He holds a degree in journalism from Emerson College. Send tips or pitches to samsonamore@dot.la and find him on Twitter @Samsonamore.

How Women’s Purchasing Power Is Creating a New Wave of Economic Opportunities In Sports
Samson Amore

According to a Forbes report last April, both the viewership and dollars behind women’s sports at a collegiate and professional level are growing.

Read moreShow less
https://twitter.com/samsonamore
samsonamore@dot.la
LA Tech Week Day 5: Social Highlights
Evan Xie

L.A. Tech Week has brought venture capitalists, founders and entrepreneurs from around the world to the California coast. With so many tech nerds in one place, it's easy to laugh, joke and reminisce about the future of tech in SoCal.

Here's what people are saying about the fifth day of L.A. Tech Week on social:

Read moreShow less

LA Tech Week: How These Six Greentech Startups Are Tackling Major Climate Issues

Samson Amore

Samson Amore is a reporter for dot.LA. He holds a degree in journalism from Emerson College. Send tips or pitches to samsonamore@dot.la and find him on Twitter @Samsonamore.

LA Tech Week: How These Six Greentech Startups Are Tackling Major Climate Issues
Samson Amore

At Lowercarbon Capital’s LA Tech Week event Thursday, the synergy between the region’s aerospace industry and greentech startups was clear.

The event sponsored by Lowercarbon, Climate Draft (and the defunct Silicon Valley Bank’s Climate Technology & Sustainability team) brought together a handful of local startups in Hawthorne not far from LAX, and many of the companies shared DNA with arguably the region’s most famous tech resident: SpaceX.

Read moreShow less
https://twitter.com/samsonamore
samsonamore@dot.la
RELATEDEDITOR'S PICKS
Trending